Projects per year
Personal profile
Biography
A/Prof David Pook is a Medical Oncologist who performs clinical research through the School of Clinical Sciences and translational research with the Prostate Cancer Research Program in the Department of Anatomy and Developmental Biology. A/Prof Pook's research work is directed towards the identification and testing of novel agents in genitourinary cancers.
Education/Academic qualification
Medicine, FRACP, Royal Australasian College of Physicians (RACP)
Medical Oncology, MD, Targeting Therapy in Colon Cancer, University of Melbourne
Medical Science, BMedSci, University of Tasmania
Medicine, MBBS (Hons), University of Tasmania
External positions
Medical Oncologist, Monash Health
2010 → …
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 1b, Open-Label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-Resistant Prostate Cancer
Pook, D. (Primary Chief Investigator (PCI))
15/06/26 → 14/06/31
Project: Research
-
An Interventional Phase 1b/2 Study to Evaluate the Safety and Efficacy of PF-08634404 Monotherapy and in Combination With Other Anticancer Agents in Adult Participants With Locally Advanced or Metastatic Renal Cell Carcinoma
Pook, D. (Primary Chief Investigator (PCI))
2/06/26 → 1/06/31
Project: Research
-
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
Pook, D. (Primary Chief Investigator (PCI))
29/05/26 → 28/11/27
Project: Research
-
AN INTERVENTIONAL PHASE 1b/2, OPEN-LABEL STUDY TO INVESTIGATE THE TOLERABILITY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF-08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
Pook, D. (Primary Chief Investigator (PCI))
14/05/26 → 13/05/31
Project: Research
-
Redefining genotyping in metastatic prostate cancer: a liquid biopsy strategy for equitable access
Kwan, E. (Primary Chief Investigator (PCI)), Herbison, H. (Associate Investigator (AI)), Pook, D. (Associate Investigator (AI)), Anton, A. (Associate Investigator (AI)), Tran, B. (Associate Investigator (AI)), Inderjeeth, A. J. (Associate Investigator (AI)), Beck, S. (Associate Investigator (AI)), George, A. (Associate Investigator (AI)), Chan, S. (Associate Investigator (AI)), Miranzadeh, S. (Associate Investigator (AI)), Taylor, R. (Associate Investigator (AI)), Lawrence, M. (Associate Investigator (AI)), Parente, P. (Associate Investigator (AI)) & Davis, I. (Associate Investigator (AI))
1/01/26 → 1/11/27
Project: Research
-
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
Inderjeeth, A. J., Martin, A. J., Zielinski, R. R., Begbie, S., Cheung, L., Chowdhury, S., Frydenberg, M., Horvath, L. G., Joshua, A. M., Lawrence, N. J., Marx, G., McCaffrey, J., McDermott, R. S., McJannett, M., North, S. A., Parnis, F., Parulekar, W. R., Pook, D. W., Reaume, M. N. & Sandhu, S. & 13 others, , 1 Apr 2026, In: European Urology Oncology. 9, 2, p. 396-403 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Link opens in a new tab Citation (Scopus) -
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide
Talmor, B., Harris, C. A., Gianacas, C., Pook, D., Tan, T. H., Davis, I. D., Krieger, L., Marx, G., Anton, A., Sharma, S., Goh, J. C., Xu, K., Pranavan, G., Dhillon, H. M., Antonarakis, E. S., Denmeade, S. R., Horvath, L., Oakes, S. R., Allen, R. & Fontela, A. & 4 others, , 1 Apr 2026, In: European Urology Oncology. 9, 2, p. 472-478 7 p.Research output: Contribution to journal › Article › Other › peer-review
-
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)
Conduit, C., Inderjeeth, A. J., Allen, R., Martin, A. J., Parulekar, W., Mulroe, E., McJannett, M., Zielinski, R. R., Thomson, A., Tan, T. H., Sandhu, S. K., Reaume, M. N., Pook, D. W., North, S. A., Marx, G. M., Joshua, A., Horvath, L., McDermott, R., Chowdhury, S. & Chi, K. N. & 5 others, , 1 Mar 2025, In: Future Oncology. 21, 6, p. 627-636 10 p.Research output: Contribution to journal › Article › Other › peer-review
Open Access1 Link opens in a new tab Citation (Scopus) -
Intravesical gemcitabine and docetaxel vs. re-induction Bacillus Calmette Guerin as first-line salvage therapy for non-muscle invasive bladder cancer
Lim, K. Y. Y., Huynh, T. N. A., Wei, G., Kuriakose, J., Fazli, O., Pook, D., Ransley, S., Downie, J., Donnellan, S. & Ranasinghe, W., Apr 2025, In: BJUI Compass. 6, 4, 3 p., e70012.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Link opens in a new tab Citations (Scopus) -
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Sandhu, S., Nguyen, A., Weickhardt, A., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Gedye, C., Rutherford, N. K., Kumar, A. S. R., Pook, D., Ramdave, S. & Nadebaum, D. P. & 19 others, , Mar 2025, In: The Lancet Oncology. 26, 3, p. 291-299 9 p.Research output: Contribution to journal › Article › Research › peer-review
68 Link opens in a new tab Citations (Scopus)